Point-of-Care Testing: An Introduction

Annals of Pharmacotherapy

Volumn 38, Issue 1, 2004, Pages 119-125

  Gutierres, Sheryl L ^a   Welty, Timothy E ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b SAMFORD UNIVERSITY   (United States)

Author keywords

Ambulatory care; Clinical Laboratory Improvement Amendments; Point of care testing

Indexed keywords

CLINICAL LABORATORY; COMPARATIVE STUDY; ECONOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL INFORMATION SYSTEM; HUMAN; LEGAL ASPECT; MASS COMMUNICATION; MEDICAL DECISION MAKING; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PRIORITY JOURNAL; REVIEW; TECHNOLOGY; TREATMENT OUTCOME;

EID: 0346992344     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D212     Document Type: Review

References (28)

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
2. Medicare conferees support medication therapy management by pharmacists. American College of Clinical Pharmacy. http://capwiz.com/accp/issue/alert/?alertid=3425166&type:CU (accessed 2003 Oct 31).
3. Kost GJ. Guidelines for point-of-care testing: improving patient outcomes. Am J Clin Pathol 1995;104(suppl 1):S111-27.
4. Point of Care Net. www.pointofcare.net/definitions.htm (accessed 2003 Sept 28).
5. Hudson MP, Christenson RH, Newby LK, Kaplan AL, Ohman EM. Cardiac markers: point of care testing. Cin Chim Acta 1999;284:223-37.
6. Kost GJ. Preventing medical errors in point-of-care-testing security, validation, performance, safeguards, and connectivity. Arch Pathol Lab Med 2001;125:1307-15.
7. Koch-Weser J, Duhme DW, Greenblatt DJ. Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clin Pharmacol Ther 1974;16:284-7.
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
9. Nichols JH, Kickler TS, Dyer KL, Humbertson SK, Cooper PC, Maughan WL, et al. Clinical outcomes of point-of-care testing in the interventional radiology and invasive cardiology setting. Clin Chem 2000;46:543-50.
10. Jobes DR, Schaffer GW, Aitken GL. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac interventions. J Thorac Cardiovasc Surg 1995;110:36-45.
11. Becker RC, Cyr J, Carrao JM, Ball SP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. Am Heart J 1994;128:719-23.
12. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-8.
13. Gravelee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99:518-27.
14. Despotis GJ, Joist JH, Goodnough LT. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997;43:1684-96.
15. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: hyperlipidemia. J Am Pharm Assoc (Wash) 2000;40:157-65.
16. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
17. Rupp MT, McCallian DJ, Sheth KK. Developing and marketing a community pharmacy-based asthma management program. J Am Pharm Assoc (Wash) 1997;NS37:694-9.
18. Winkelman JW, Wybenêa DR, Tanasijevic MJ. The liscal consequences of central vs distributed testing of glucose. Clin Chem 1994;40:1628-30.
19. Lee-Lewandrowski E, Laposata M, Eschenback K, Camooso C, Nathan DM, Godine JE, et al. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. Am J Med 1994;97:222-3.
20. Nosanchuj JS, Keefner R. Cost analysis of point-of-care laboratory testing in a community hospital. Am J Clin Pathol 1995;103:240-3.
21. Boldt J, Watz G, Triem J, Suttner S, Kumle B. Point-of-care (POC) measurement of coagulation after cardiac surgery. Intensive Care Med 1998;24:1187-93.
22. St-Louis P. Status of point-of-care testing: promise, realities, and possibilities. Clin Biochem 2000;33:427-40.
23. Halpern MT, Palmer CS, Simpson KN, Chesley FD, Luce BR, Suyderhoud JP, et al. The economic and clinical efficiency of point-of-care testing for critically ill patients: a decision-analysis model. Am J Med Qual 1998;13:3-12.
24. Grieve R, Beech R, Vincent J, Mazurkiewicz J. Near patient testing in diabetes clinics: appraising the costs and outcomes. Health Technol Assess 1999;3:Number 15 (Executive summary).
25. Schumock GT. How to develop a business plan for clinical pharmacy services: a guide for managers and clinicians. Kansas City: American College of Clinical Pharmacy, 2001.
26. Rosenthal WM. Establishing a pharmacy-based laboratory service. J Am Pharm Assoc 2000;40:146-56.
27. Kohn LT, Corrigan JM, Donaldson MS. eds. Committee on Quality of Health Care in America. Institute of Medicine. To err is human: building a safer health system. Washington, DC: National Academic Press; 2000.
28. United States Department of Labor. Occupational Safety and Health Administration. www.osha.gov.html (accessed 2003 May 8)